A share price of Akebia Therapeutics Inc [AKBA] is currently trading at $1.93, up 3.76%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AKBA shares have gain 7.22% over the last week, with a monthly amount drifted -9.81%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on August 28, 2023, and kept the price target unchanged to $3.75. On May 31, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $4 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $2 on March 31, 2022. Needham downgraded its rating to a Hold. Mizuho downgraded its rating to Neutral for this stock on March 31, 2022, and downed its price target to $2. In a note dated March 31, 2022, H.C. Wainwright downgraded an Neutral rating on this stock and revised its target price from $10 to $2.
Akebia Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.80 and $2.48. Currently, Wall Street analysts expect the stock to reach $6.5 within the next 12 months. Akebia Therapeutics Inc [NASDAQ: AKBA] shares were valued at $1.93 at the most recent close of the market. An investor can expect a potential return of 236.79% based on the average AKBA price forecast.
Analyzing the AKBA fundamentals
Trailing Twelve Months sales for Akebia Therapeutics Inc [NASDAQ:AKBA] were 169.88M which represents -10.98% decline. Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.27%, and Net Profit Margin reading is -0.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is 1.3 and Total Capital is -0.25. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.96.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8533 points at the first support level, and at 1.7767 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9733, and for the 2nd resistance point, it is at 2.0167.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Akebia Therapeutics Inc [NASDAQ:AKBA] is 1.52. In addition, the Quick Ratio stands at 1.21 and the Cash Ratio stands at 0.52. Considering the valuation of this stock, the price to sales ratio is 2.48.
Transactions by insiders
Recent insider trading involved Butler John P., CEO and President, that happened on Mar 03 ’25 when 46409.0 shares were sold. SVP, Chief Medical Officer, Burke Steven Keith completed a deal on Mar 03 ’25 to sell 7144.0 shares. Meanwhile, Officer Burke Steven Keith bought 7144.0 shares on Mar 03 ’25.
